



1FW

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/802,432
	Filing Date	March 17, 2004
	First Named Inventor	Certa
	Art Unit	
	Examiner Name	
Total Number of Pages in This Submission	Attorney Docket Number	21574

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	USPTO Form 1449; References	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Dennis P. Tramaloni
Signature	
Date	June 15, 2004

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	Dennis P. Tramaloni		
Signature		Date	June 15, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventor(s) Ulrich Certa, Stefan Foser

Group:

Serial No. 10/802,432, filed March 17, 2004

Examiner:

Docket No. 21574

For: GENE TRANSCRIPTION ASSAY METHOD

INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110
June 15, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.


Document A1 listed on form PTO 1449 is not being submitted because it is a US Patent. Documents B1 – B9 and C1 – C16 are enclosed.

Consideration of all the documents cited on Form PTO-1449 is requested.

Serial No. 10/802,432
Filed: March 17, 2004

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application, no fee is due.

Respectfully submitted,



Attorney for Applicant(s)
Dennis P. Tramaloni
(Reg. No. 28,542)
340 Kingsland Street
Nutley, New Jersey 07110
Telephone: (973) 235-4475
Telefax: (973) 235-2363

143144

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Application Number	10/802,432
		Filing Date	March 17, 2004
		First Name Inventor	Certa
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	21574
Sheet 1	of 1		

TRADEMARK		U.S. PATENT DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	A1	US5837832		Affymetrix, Inc.	11-17-1998
	</				

FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ²
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
	B1	EP0834575			Affymetrix, Inc.	11-28-2001	
	B2	EP0834576			Affymetrix, Inc.	01-16-2002	
	B3	EP0510356			F. Hoffman-La Roche AG	01-27-1999	
	B4	EP0593868			F. Hoffman-La Roche AG	04-15-1998	
	B5	EP0809996			F. Hoffman-La Roche AG	04-02-2003	
	B6	WO96/31622			ISIS INNOVATION LIMITED	10-10-1996	
	B7	WO98/30883			Affymetrix, Inc.	07-16-1998	
	B8	WO97/10365			AFFYMAX TECHNOLOGIES N.V.	03-20-1997	
	B9	WO02/18633			F. Hoffman-La Roche AG	03-07-2002	
Examiner Signature		Date Considered					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Complete if Known	
				Application Number	10/802,432
				Filing Date	March 17, 2004
				First Name Inventor	Certa
				Group Art Unit	
				Examiner Name	
Sheet	2	Of	2	Attorney Docket Number	21574

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	C1	P. BAILON et al., Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol0conjugated Interferon-2a for the treatment of hepatitis C, Bioconjugate Chem. 12 (2001), 195-202	
	C2	Z.Z. CHONG, et al., Hematopoietic factor erythropoietin foster neuroprotection through novel signal transduction cascades, J. Cereb.Blood Flow Metab., 22 (2002), 503-514	
	C3	CK GLASS: Some new twists in the regulation of gene expression by throid hormone and retinoic acid receptors, J. Endorinol, 150 (1996), 349-357	
	C4	T. HANADA and A. YOSHIMURA: Regulation of cytokine signaling and inflammation, Cytokine Growth Factor Rev., 13 (2002), 413-421	
	C5	J.M. HARRIS, et. al., Pegylation: A novel process for modifying pharmacokinetics, Clin. Pharmacokinet. 40 (2001), 539-551	
	C6	KLAUS, et al., J. Mol. Biol. 274 (1997) 661-675	
	C7	R. MANDLER et al., Modification in syntheses strategy..., Bioconjugate Chemistry, 13 (2002), 786-791	
	C8	G.S. MCKNIGHT: Cyclic AMP second messenger systems, Curr. Opin. Cell Biol., 3 (1991) 213-217	
	C9	L. MULCAHY: the erythropoietin receptor, Semin. Oncol. 28 (2001), 19-23	
	C10	Y. NISHIO, et al., Cilostazol, a cAMP phosphodiesterase inhibitor..., Hormone & Metabolic Research, 29 (1997) 491-495	
	C11	A. ROWE, Retinoid X Receptors, Int. J. Biochem. Cell Biol. 29 (1997), 275-278	
	C12	Y. SATO et al., Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction, Ann. N.Y. Acad. Sci., 902 (2000), 201-207	
	C13	J.L. SPIVAK: The mechanism of action of erythropoietin, Int. J. Cell Cloning, 4 (1986) 139-166	
	C14	A.H. TALUKDER et al, Antihuman epidermal growth factor..., Clin. Cancer Res. 8 (2002), 3285-3289	
	C15	B. WAGNER, et al., 7-Benzylamino-6chloro-2piperazino-4-pyrrolidino-pteridine....Biochemical Pharmacology, 63 (2002) 659-668	
	C16	D.M. WOJCHOWSKI and T.C. HE: Signal transduction in the erythropoietin receptor system, Stem. Cells, 11 (1993), 381-392	
Examiner Signature			DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ² Applicant is to place a check mark here if English language Translation or abstract is attached.